A phase II trial of pemetrexed/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Phase 2
- Conditions
- elderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma
- Registration Number
- JPRN-UMIN000008764
- Lead Sponsor
- Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
1) history of hemoptysis (more than 2.5mL) 2) with pulmonary cavitary lesions 3) with invasion to the aorta and/or pulmonary arteries 4) tumor outcrop in main bronchus 5) history of radical thoracic radiotherapy 6) patients treated by anti-coagulation therapy complicated with brain metastasis 7) with severe infection 8) with massive pleural effusion, ascites or pericardial effusion 9) overlapped with other malignancies 10) with severe peptic ulcer 11) history of perforation in digestive tract
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method